Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma
Background/Aim: Evidence regarding first-line enfortumab vedotin plus pembrolizumab (EVP) in elderly patients with advanced urothelial carcinoma (UC), particularly those aged ≥80 years, remains limited. This study evaluated the real-world effectiveness, safety, and treatment feasibility of EVP stratified by age. Patien...